{"schema_version":"secwatch.filing_event.v1","accession":"0001764046-26-000018","form_type":"8-K","ticker":"CLVT","cik":"0001764046","company_name":"CLARIVATE PLC","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.107031+00:00","generated_at":"2026-05-16T00:51:10.455127+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clarivate Q4 revenue $617M, down 7%; pursues LS&H sale; FY26 FCF ~$400M","bullets":["Q4 net income $3.1M vs loss $191.8M; adjusted EPS $0.20 vs $0.21. Full-year adjusted EBITDA $1,001.8M.","Organic ACV grew 1.8% in FY2025; recurring revenue mix improved to 88% of total revenue.","Pursuing sale of Life Sciences & Healthcare; retained Morgan Stanley; proceeds to reduce leverage.","FY2026 outlook: Adj. EBITDA growth with ~200 bps margin expansion; FCF ~$400M at midpoint.","Returned $225M to shareholders via share repurchases in 2025 (56M shares)."],"urls":{"canonical":"https://secwatch.observer/filing/0001764046-26-000018","json":"https://secwatch.observer/filing/0001764046-26-000018.json","markdown":"https://secwatch.observer/filing/0001764046-26-000018.md","text":"https://secwatch.observer/filing/0001764046-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764046/000176404626000018/0001764046-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764046/000176404626000018/clvt-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:51:10.455127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}